Gene: ACBD6
Official Full Name: acyl-CoA binding domain containing 6provided by HGNC
Gene Summary: Enables fatty-acyl-CoA binding activity. Located in cytoplasm and nucleus. [provided by Alliance of Genome Resources, Apr 2025]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO24924 | ACBD6 Knockout cell line (HeLa) | Human | ACBD6 | 1:3~1:6 | Negative | Online Inquiry |
KO24925 | ACBD6 Knockout cell line (HCT 116) | Human | ACBD6 | 1:2~1:4 | Negative | Online Inquiry |
KO24926 | ACBD6 Knockout cell line (HEK293) | Human | ACBD6 | 1:3~1:6 | Negative | Online Inquiry |
KO24927 | ACBD6 Knockout cell line (A549) | Human | ACBD6 | 1:3~1:4 | Negative | Online Inquiry |
ACBD6 Gene Knockout Cell Lines are a cutting-edge tool tailored for researchers investigating the functional role of the ACBD6 gene within cellular systems. These cell lines are meticulously engineered through CRISPR-Cas9 technology to introduce specific deletions in the ACBD6 gene, creating a loss-of-function model that allows for precise assessment of the gene's contribution to various biological processes. This gene is known to play critical roles in lipid metabolism and intracellular transport, making the knockout model particularly valuable for studies in both genetic and metabolic disease contexts.
The primary mechanism of the ACBD6 Gene Knockout Cell Lines involves the deliberate disruption of the ACBD6 genomic sequence. This process permits researchers to eliminate the expression of the ACBD6 protein, enabling the exploration of its involvement in pathways relevant to cell growth, differentiation, and response to stress. By utilizing these knockout lines, scientists can unveil the underlying molecular mechanisms associated with ACBD6, facilitating a deeper understanding of its role in health and disease.
The scientific significance of ACBD6 Gene Knockout Cell Lines extends to various applications in research and clinical settings, especially concerning metabolic disorders and cancer biology. These models open new avenues for drug discovery and development, as they allow for the evaluation of therapeutic interventions targeting cellular pathways influenced by ACBD6. Additionally, they contribute to the identification of biomarkers for diseases linked to aberrant lipid metabolism, thereby helping to bridge gaps in current clinical knowledge.
Compared to traditional knockout strategies, the CRISPR-Cas9 approach employed in our product ensures a high efficiency of mutation incorporation and minimal off-target effects, providing robust and reproducible results. Researchers can rely on these cell lines for consistent performance in experiments aiming to elucidate the biological significance of ACBD6.
The value of ACBD6 Gene Knockout Cell Lines to researchers and clinicians cannot be overstated. With their ability to generate reliable models that mimic gene knockout conditions, these cell lines empower users to explore novel therapeutic strategies, identify potential drug targets, and fundamentally advance the field of genetic research.
Our company is committed to providing high-quality biological products that meet rigorous scientific standards. With extensive expertise in gene editing technologies and a focused approach on supporting groundbreaking research, we are dedicated to facilitating advancements in the understanding of gene function and its implications for human health.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.